X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Speaker Pelosi’s drug pricing plan could result in 56 fewer new medicines over 10 years

By Juliet Johnson  |    November 21, 2019
A new analysis from economic consulting firm Vital Transformation shows that Speaker Nancy Pelosi’s drug pricing plan, H.R.3, could result in at least 56 fewer innovative medicines for patients...   Read More

Pelosi’s radical plan would leave ALS patients behind

By Tom Wilbur  |    October 15, 2019
Last month, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and...   Read More

ICYMI: Fighting for a cure to ALS

By Anne McDonald Pritchett, PhD  |    September 25, 2019
Yesterday at The Atlantic Festival, I had the chance to speak with Amy, a biopharmaceutical researcher focused on amyotrophic lateral sclerosis (ALS). As a young girl, Amy’s father inspired her to...   Read More

New report shows over 500 medicines in development for neurological disorders

By Andrew Powaleny  |    April 18, 2018
Neurological disorders, which include more than 1,000 conditions that disrupt the brain and nervous system, affect an estimated 100 million Americans, nearly one third of the U.S. population....   Read More

New PhRMA Report: Medicines in development for patients with rare diseases demonstrate the promise of innovation

By Ieva M. Augstums  |    May 9, 2016
Today, there are 7,000 known rare diseases, or diseases that affect fewer than 200,000 people in the United States. But those suffering from the impact of these diseases have more hope today...   Read More

Because One Day Isn't Enough

By PhRMA Staff  |    February 28, 2011
Today is Rare Disease Day, a day meant to raise awareness of the 25 million Americans living with diseases that are often little-known and often, unfortunately, undertreated. In conjunction with Rare...   Read More

Searching for Success in ALS

By PhRMA Staff  |    February 10, 2011
Yesterday, our friends at ALS Advocacy Tweeted about the Chart Pack: "Need some #ALS success charts in the next edition!" They can rest assured that America's biopharmaceutical research companies are...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates